PDS Biotechnology Corp. PDSB 深 滬
已收盤 05-22 16:00:00 美东时间
1.20
+0.040
+3.45%
華盛通- 最 高1.28
- 今 開1.19
- 成交量 116.70万股
- 最 低 1.18
- 昨 收 1.16
- 總市值 6697.88万
- 52周最高 1.915
- 市盈率 靜 --
- 換手率 2.09%
- 52周最低 0.5068
- 委 比 -8.15%
- 總股本 5581.57万
- 歷史最高 17.85
- 量 比 1.10
- 振 幅 8.62%
- 歷史最低 0.5068
- 每 手 1
- 風險率 0.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Palatin Technologies shares are trading higher after the company reported better-than-expected Q1 EPS results.
Palatin Technologies shares are trading higher after the company reported bette...
05-14 01:42
PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript
PDS Biotechnology (NASDAQ:PDSB) reported first-quarter financial results on Wed...
05-13 20:26
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
PDS Biotechnology Q1 EPS $(0.13) Beats $(0.15) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 38.1 percent increase over losses of $(0.21) per share from
05-13 19:01
美股大行评级 | 大行互评！花旗银行、贝莱德获多家大行上调目标价；哈里伯顿、强生、Patterson获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Knightscope"买入"评级，目标价从25美元升至26美元；杰富瑞：维持Allogene疗法"买入"评级，目标价从6美元升至10美元
04-16 10:14
Why Is PDS Biotechnology Stock Gaining Wednesday?
PDS Biotechnology says Phase 2 data show higher response rates and survival trends in colorectal cancer and prostate cancer studies.
04-16 01:14
PDS Biotechnology Announces Publication Of Clinical And Immunological Biomarker Data From Stage 1 Of Phase 2 Trial Evaluating Its Tumor-Targeted IL-12 Immunocytokine, PDS01ADC, In March 10 Issue Of JCO Oncology Advances
78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35%Trials performed in
04-15 21:04
PDS Biotechnology Q4 EPS $(0.14) Beats $(0.20) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is a 33.33 percent increase over losses of $(0.21) per share from
03-30 21:41
PDS Biotechnology Reports Early Positive Results In Cancer Study, Tweaks Late-Stage Cancer Trial To Speed Up Potential Approval
PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and
03-30 19:23
Earnings Scheduled For March 30, 2026
Companies Reporting Before The Bell • Liberty All Star Equity (NYSE:USA) is est...
03-30 19:11
